Peter Barrett, Ph.D.
Chairman, Momenta Pharmaceuticals Inc.
Dr. Barrett co-founded Celera Genomics with Dr. J. Craig Venter and the Applera Corporation management team. He held the positions of Executive Vice President and Chief Business Officer at Celera, where the team announced the first successful sequencing of the human genome within two years of the founding of the company.

John K. Clarke
Managing General Partner, Cardinal Partners
Mr. Clarke founded Cardinal Partners in 1997. He has founded and served as interim CEO of a number of portfolio companies, including Alkermes, Inc., Arris Pharmaceuticals, Inc., the DNX Corporation, and Cubist Pharmaceuticals.

Alan L. Crane
Former Chief Executive Officer, Momenta
Mr. Crane was previously Senior Vice President, Global Corporate Development for Millennium Pharmaceuticals where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions and licensing activities.

Marsha H. Fanucci
Senior Vice President & Chief Financial Officer, Millennium Pharmaceuticals, Inc.
Ms. Fanucci is presently Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals, Inc. Previously, she was Vice President of Corporate Development and Strategy at Genzyme. Ms. Fanucci has also served as Vice President and Managing Director at Arthur D. Little Inc.

Paul D. Goldenheim, M.D.
Former President of TransForm Pharmaceuticals, Inc.
Prior to joining TransForm, Dr. Goldenheim held multiple positions at Purdue Pharma, L.P and the Purdue Frederick Company of Stamford, Connecticut, including the positions of Executive Vice President and Chief Scientific Officer, and Executive Vice President, Worldwide Research and Development. Dr. Goldenheim is an author on numerous scientific publications and the inventor on a number of pharmaceutical patents. Dr. Goldenheim also serves on the boards of directors of a few privately-held and non-profit entities.

Peter Barton Hutt, LLB, LLM
Partner, Covington & Burling
As former Chief Counsel for the Food and Drug Administration, Mr. Hutt drafted many of the current FDA regulations. Mr. Hutt currently serves as a member of the Institute of Medicine of the National Academy of Sciences and teaches a course on Food and Drug Law at Harvard Law School. He has published numerous papers on food and drug law and health policy.

Robert S. Langer, Jr., Sc.D.
Momenta Co-Founder & Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering, MIT
Dr. Langer is the former Chairman of the FDA Science Board, the FDA's highest advisory board. He has written 780 articles, 450 abstracts, and has nearly 500 issued or pending patents. Dr. Langer has received over 100 major awards, including the 2002 Charles Stark Draper Prize, considered the world's most prestigious engineering prize.

Stephen T. Reeders, D.M., MRCP
Chief Executive Officer, MVM Limited
Dr. Reeders is founder and Chief Executive Officer of MVM Limited. In this role, he has co-founded three biotechnology companies and currently serves as a Board Member of Nova Science Limited, Vasca Inc., and Oxxon Pharmaceuticals, Inc. Prior to founding MVM, Dr. Reeders led healthcare investing at Saunders, Karp & Megrue and served on the faculty at Yale University.

Ram Sasisekharan, Ph.D.
Momenta Co-Founder & Professor of Biological Engineering, MIT
Dr. Sasisekharan's research on complex polysaccharides has led to 90 publications and 30 patents, including the core technologies of Momenta. He has won both the Burroughs Wellcome and Beckman Foundation Young Investigator Awards and was the recipient of 1998, 1999, 2000, and 2001 CaPCure Awards from the CaPCure Foundation. Dr. Sasisekharan serves on the steering committee of the Consortium for Functional Glycomics.

Bennett M. Shapiro, M.D.
Executive Vice President, Merck & Co., Inc. (Retired)
Dr. Shapiro served as an Executive Vice President at Merck & Co. from 1990 to 2003. Dr. Shapiro is the former head of Worldwide Licensing and External Research at Merck; prior to that, he served as the head of basic and preclinical research at Merck & Co. and as Chairman of the Biochemistry department at University of Washington.

Craig A. Wheeler
Momenta President & Chief Executive Officer
Mr. Wheeler was previously President of Chiron BioPharmaceuticals, the biotechnology division of Chiron Corporation, where he was responsible for critical facets of the division’s commercial, discovery and development, and business development activities